Publication Cover
Hemoglobin
international journal for hemoglobin research
Volume 33, 2009 - Issue 5
164
Views
21
CrossRef citations to date
0
Altmetric
PROCEEDINGS 17TH ICOC Shenzhen, PR China, November 2007

Advances in the Prevention and Treatment are Changing Thalassemia from a Fatal to a Chronic Disease. Experience from a Cyprus Model and its Use as a Paradigm for Future Applications

&
Pages 287-295 | Published online: 09 Oct 2009

REFERENCES

  • Weatherall DJ, Clegg JB. Inherited hemoglobin disorders: an increasing global health problem. Bull World Health Organ. 2001; 79(8):704–712.
  • Kontoghiorghes GJ, Eracleous E, Economides Ch, Kolnagou A. Advances in iron overload therapies. Prospects for effective use of deferiprone (L1), deferoxamine, the new experimental chelators ICL670, GT56-252, L1NAll and their combinations. Curr Med Chem. 2005; 12(23):2663–2681.
  • World Health Organization. Community control of hereditary anaemias. Bull. WHO. 1983; 61(1):63–80.
  • Kontoghiorghes GJ. Ethical issues and risk/benefit assessment on iron chelation therapy: advances with deferiprone/deferoxamine combinations and concerns about the safety, efficacy and cost of deferasirox. Hemoglobin. 2008; 32(1–2):1–15.
  • Zurlo MG, De Stefano P, Borgna-Pignatti C, Survival and causes of death in thalassaemia major. Lancet. 1989; 2(8653):27–30.
  • Kyriacou K, Michaelides Y, Senkus R, Ultrastructural pathology of the heart in patients with β-thalassemia major. Ultrastruct Pathol. 2000; 24(2):75–81.
  • Aessopos A, Farmakis D, Hatziliami A, Cardiac status in well-treated patients with thalassaemia major. Eur J Haematol. 2004; 73(5):359–366.
  • Modell B, Khan M, Darlison M. Survival in β-thalassaemia major in the UK: data from the UK Thalassaemia Register. Lancet. 2000; 355(9220):2051–2052.
  • Borgna-Pignatti C, Cappellini MD, De Stefano P, Cardiac morbidity and mortality in deferoxamine- or deferiprone-treated patients with thalassemia major. Blood. 2006; 107(9):3733–3737.
  • Telfer P, Coen PG, Christou S, Survival of medically treated thalassaemia patients in Cyprus. Trends and risk factors over the period 1980–2004. Haematologica. 2006; 91(9):1187–1192.
  • Kuliev A, Rechitsky S, Verlinsky O, Preimplantation diagnosis and HLA typing for hemoglobin disorders. Reprod Biomed Online. 2005; 11(3):362–370.
  • Andreani M, Nesci S, Lucarelli G, Long-term survival of ex-thalassemic patients with persistent mixed chimerism following bone marrow transplantation. Bone Marrow Transplant. 2000; 25(4):401–404.
  • Mavrogeni SI, Gotsis ED, Markussis V, T2 relaxation time study of iron overload in β-thalassemia. MAGMA. 1998; 6(1):7–12.
  • Anderson LJ, Wonke B, Prescott E, Comparison of effects of oral deferiprone and subcutaneous desferrioxamine on myocardial iron concentrations and ventricular function in β-thalassaemia. Lancet. 2002; 360(9332):516–520.
  • Di Bartolomeo P, Santarone S, Di Bartolomeo E, Long term results of survival in patients with thalassemia major treated with bone marrow transplantation. Am J Hematol. 2008; 83(7):528–530.
  • Kolnagou A, Kontoghiorghes GJ. Effective combination therapy of deferiprone and deferoxamine for the rapid clearance of excess cardiac iron and the prevention of heart disease in thalassemia. The protocol of the International Committee on Oral Chelators. Hemoglobin. 2006; 30(2):239–249.
  • Kolnagou A, Michaelides Y, Kontos C, Myocyte damage and loss of myofibers is the potential mechanism of iron overload toxicity in congestive cardiac failure in thalassemia. Complete reversal of the cardiomyopathy and normalization of iron load by deferiprone. Hemoglobin. 2008; 32(1–2):17–28.
  • Peng CT, Chow KC, Chen JH, Safety monitoring of cardiac and hepatic systems in β‐thalassaemia patients with chelating treatment in Taiwan. Eur J Haematol. 2003; 70(6):392–397.
  • Pennell DJ, Berdoukas V, Karagiorga M, Randomized controlled trial of deferiprone or deferoxamine in β-thalassemia major patients with asymptomatic myocardial siderosis. Blood. 2006; 107(9):3738–3744.
  • Kontoghiorghes GJ. Prospects for introducing deferiprone as potent pharmaceutical antioxidant. Front Biosci. 2009; E1:161–178.

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.